PRISM BioLab、米国製薬大手イーライリリー・アンド・カンパニーとライセンスおよび共同研究契約を締結
Commentary on Protein-Protein and Protein-Peptide Interactions, peptidomimetics and related topics in drug discovery.

PRISM BioLab、大原薬品工業 とライセンス契約に基づくマイルストン達成のお知らせ

TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing...


The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein Interactions (PPIs): Current Strategies for the Development of New Drugs” presents a new method to generate small-molecules PPI inhibitors using only a sequence of a binding peptide. Potent and active PPI inhibitor peptides can be readily generated by various...


PRISM BioLab’s proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm. In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup,...

株式会社PRISM BioLab、エーザイ株式会社より資金調達

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...

Scroll to top